Harrow, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Harrow, Inc. (HROW) had Deferred Tax Assets, Operating Loss Carryforwards of $12.33 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-02
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $12.33M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $2.45M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $4.67M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $9.40M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $12.33M 10-K · filed 2026-03-02 | |
| 2024-12-31 | $2.45M 10-K · filed 2026-03-02 | |
| 2023-12-31 | $4.67M 10-K · filed 2025-03-27 | |
| 2022-12-31 | $9.40M 10-K · filed 2024-03-19 | |
| 2021-12-31 | $12.34M 10-K · filed 2023-03-23 | |
| 2020-12-31 | $19.68M 10-K · filed 2022-03-10 | $19.68M 10-K · filed 2021-03-08 |
| 2019-12-31 | $19.83M 10-K · filed 2021-03-08 | |
| 2018-12-31 | $19.73M 10-K · filed 2020-03-13 | |
| 2017-12-31 | $17.41M 10-K · filed 2019-03-12 | |
| 2016-12-31 | $21.55M 10-K · filed 2018-03-08 | $21.54M 10-K · filed 2017-03-21 |
| 2015-12-31 | $15.10M 10-K · filed 2017-03-21 | |
| 2013-12-31 | $10.92M 10-K · filed 2016-03-23 | |
| 2012-12-31 | $5.44M 10-K · filed 2013-03-18 | |
| 2011-12-31 | $4.89M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |